Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pfizer Inc. (PFE) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, with AI‑powered tools to help interpret complex documents. As a large issuer in the pharmaceutical preparation manufacturing industry, Pfizer files a wide range of reports that are important for understanding its operations, capital structure and risk profile.
Investors can review Form 8‑K current reports that describe material events such as financial results, public offerings of notes, acquisitions and guidance updates. Recent 8‑K filings detail second‑ and third‑quarter 2025 financial results, full‑year 2025 and 2026 revenue and adjusted EPS guidance, a multi‑tranche public offering of senior notes with maturities extending to 2065, and the completed acquisition of Metsera, a company developing GLP‑1‑based obesity therapies.
Pfizer’s 8‑Ks also reference shelf registration statements and supplemental indentures governing its debt securities, as well as underwriting and pricing agreements with major investment banks. These filings help users track how Pfizer raises long‑term capital and manages its balance sheet. Other 8‑Ks furnish press releases under Regulation FD, including guidance updates that outline expected revenue contributions from COVID‑19 products and the impact of loss of exclusivity on certain medicines.
On Stock Titan, AI‑generated summaries highlight the key points of lengthy filings, explaining in plain language what new debt offerings, acquisitions, guidance changes or other events may mean for the company. Users can quickly identify which exhibits relate to indentures, legal opinions or merger agreements, and can follow how Pfizer’s financing activities and strategic transactions evolve over time.
In addition to 8‑Ks, this page links to Pfizer’s other core SEC reports, such as annual and quarterly filings, where available. Together, these documents provide a regulatory record of Pfizer’s financial performance, risk factors, capital markets activity and major corporate actions, with AI assistance to make the information more accessible.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 21 Phantom Stock Units on March 31, 2026 under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock and is valued at $28.08 per unit.
These units are settled in cash after his separation from service and can be reallocated by him into another investment option at any time. Following this award, Bourla holds a total of 759,049 Phantom Stock Units directly.
Taraporevala Cyrus reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director Cyrus Taraporevala received a grant of 1,386.834 phantom stock units tied to Pfizer common stock, valued at $27.04 per unit. After this award, his reported balance increased to 27,139.547 phantom stock units.
Each unit represents one phantom share of common stock and forms part of deferred director compensation, including dividend equivalents. These units will be settled in cash or common stock, at the director’s election, after he retires from the Board of Directors, making this a compensation and deferral event rather than an open-market trade.
SMITH JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director James C. Smith received a grant of 1,664.2010 Phantom Stock Units linked to common stock as deferred board compensation. The units were valued at $27.0400 per unit and increase his phantom stock balance to 170,424.7630 units after the transaction.
Each unit represents one phantom share of Pfizer common stock and includes dividend equivalents. The award is part of deferred director compensation that will be settled in cash or common stock, at Smith’s election, after he retires from the Board of Directors, rather than an open-market purchase.
Quincey James reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director James Quincey received a grant of phantom stock units as deferred board compensation. On March 27, 2026, he was awarded 1,433.062 Phantom Stock Units, each linked to one share of Pfizer common stock and valued at $27.04 per unit. Following this award, his reported balance rose to 77,317.538 phantom units. These units represent deferred director compensation, including dividend equivalents, and will be settled in cash or common stock at his election after he retires from the Board.
NARAYEN SHANTANU reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Shantanu Narayen received a compensation grant of 1,849.112 Phantom Stock Units tied to Pfizer common stock. The units were credited at a reference price of $27.04 per unit and increase his phantom stock balance to 187,925.141 units.
Each unit represents one phantom share of common stock and forms part of deferred director compensation, including dividend equivalents. According to the disclosure, these units will be settled in cash or Pfizer common stock, at the director's election, after he retires from the Board.
Echevarria Joseph reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Joseph Echevarria received a grant of 1,710.429 Phantom Stock Units tied to Pfizer common stock. Each unit represents one phantom share of common stock and was valued at $27.04 per unit on the grant date. After this award, his reported phantom unit balance increased to 153,398.145 units. These units represent deferred director compensation, including dividend equivalents, and will be settled in cash or Pfizer common stock at his election after he retires from the Board of Directors.
Buckley Mortimer J reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Mortimer J. Buckley received a grant of 1,386.834 Phantom Stock Units on deferred compensation terms. Each unit represents one phantom share of common stock valued at $27.04. Following the award, Buckley holds 16,704.585 Phantom Stock Units, which will be settled in cash or stock after his retirement from the Board.
Pfizer Inc. ownership filing: The Vanguard Group filed an amendment reporting 0 shares of Pfizer common stock, representing 0% of the class. The filing states that on January 12, 2026 Vanguard completed an internal realignment and now reports beneficial ownership of certain subsidiaries separately in reliance on SEC Release No. 34-39538 (January 12, 1998).
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. It lists Vanguard's address as 100 Vanguard Blvd., Malvern, PA and reiterates that no single outside person holds more than 5% of the class according to the disclosure.
Pfizer Inc. reported that Chairman and CEO Albert Bourla acquired 1,630 phantom stock units linked to Pfizer common stock. The units were granted at a reference price of $26.58 per unit under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan.
Each unit tracks one share of common stock but is settled in cash after his separation from service rather than in actual shares. Following this grant, Bourla holds a total of 759,400 phantom stock units, providing cash-based exposure to Pfizer’s share value as part of his long-term compensation.